Page 4 - Benefit Managers News Today

Juliana Reed, MS, believes that there should be legislative incentives and preferred status for lower cost biosimilars in all government programs, with robust competition and accountability for PBMs not to limit access.

The Biosimilars Forum is concerned with the limited access to lower-cost biosimilars, specifically regarding the 8 adalimumab biosimilars set to launch in July, due to pharmacy benefits managers controlling access to 80% of the US market.

Treasury Department and IRS Release Preliminary Guidance on Semiconductor Tax Credit. On March 23, the Treasury Department and IRS published proposed regulations for implementing the...

Senate voted to end COVID 19 national emergency other action related to healthcare was at committee level. FY 2024 budget hearings continued and other health related hearings included House Energy and Commerce Committee hearing focused on transparency and competition

Dear Colleague, The term "mom and pop" business had always bothered me. I thought it sounded a bit condescending and dismissive when I would hear representatives from big businesses talk about it, almost like they were giving small business owners a little pat on the head. But Wednesday was "Mom and Pop Business Owner's Day," and my attitude about the phrase evolved during a week in D.C. when independent pharmacies were in the spotlight.

Sen. Ron Wyden (D-Ore.) says it’s time for Congress to shine a light on a business with extraordinary ...

This Week in Washington: HHS Secretary appears before Senate Finance and Senate Appropriations Committees...

State leaders need to push back on the pressure they’ll get to undermine pharmacy benefit managers and the valuable services they provide to patients.

Small independent drug stores say the PBMs put them at a competitive disadvantage.

Small independent drug stores say the PBMs put them at a competitive disadvantage.